Source: International Congress 2016 – Update on drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Daniel Wirth (Neuss, Germany), Daniel Wirth, Ramesh Dass, Robert Hettle. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. Eur Respir J 2016; 48: Suppl. 60, 2681

Member's Comments

No comment yet.

Related content which might interest you: Cost-effectiveness of treating MDR-TB by adding delamanid to background regimens in Germany Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Tuberculosis: cost of illness in Germany Source: Eur Respir J 2012; 40: 143-151 Year: 2012 Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Source: Eur Respir J 2011; 38: 516-528 Year: 2011 Adherence to the recommendation of prescribing 4 drugs in the intensive phase of the standard treatment of tuberculosis in Spain Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Treatment of multidrug-resistant tuberculosis (MDR-TB) with modified shorter all-oral treatment regimen (mSTR) under operational research conditions in Belarus Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 MDR-TB guidelines: what is new on clinical management Source: ERS Webinar 2020: MDR-TB guidelines: what is new on clinical management Year: 2020 Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 MDR TB treatment results of GFATM program implementation in Tomsk, Russia Source: International Congress 2015 – Management of TB: a patient focus Year: 2015 Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Is there a need for prolonged follow up in mono-drug resistant TB? Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014 Clinical profile of MDR-TB patients and their early response to DOTS PLUS: An Indian perspective Source: Annual Congress 2013 –Tuberculosis: clinical aspects Year: 2013 Four cases, one family: A cluster of resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013